Earnings Feed
Start Free
Home/Filings/4/0001140361-11-001839
4//SEC Filing

CAVAZZA CLAUDIO 4

Accession 0001140361-11-001839

CIK 0000707511other
View on SEC.govCompany Profile

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 12:52 PM ET

Size

43.0 KB

Accession

0001140361-11-001839

Insider Transaction Report

Form 4
Period: 2011-01-05
REGENERX BIOPHARMACEUTICALS INCRGRX.OB
CAVAZZA CLAUDIO
10% Owner
Transactions
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 1 total(indirect: Indirect)
    Exercise: $0.38From: 2011-07-07Exp: 2016-01-07→ Common Stock (370,370 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05−1→ 0 total(indirect: Indirect)
    Exercise: $4.06Exp: 2011-03-16→ Common Stock (256,148 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05−1→ 0 total(indirect: Indirect)
    Exercise: $2.75Exp: 2011-12-21→ Common Stock (333,333 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 2 total(indirect: Indirect)
    Exercise: $0.38Exp: 2011-12-31→ Common Stock (333,333 underlying)
  • Purchase

    Common Stock

    2011-01-05$0.27/sh+1,296,296$350,000→ 6,348,878 total(indirect: Indirect)
  • Purchase

    Common Stock

    2011-01-05$0.27/sh+925,926$250,000→ 12,937,111 total(indirect: Indirect)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 1 total(indirect: Indirect)
    Exercise: $0.38From: 2011-07-07Exp: 2016-01-07→ Common Stock (518,518 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05−1→ 0 total(indirect: Indirect)
    Exercise: $4.06Exp: 2011-03-16→ Common Stock (22,601 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 1 total(indirect: Indirect)
    Exercise: $0.38Exp: 2011-12-31→ Common Stock (22,601 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05−1→ 0 total(indirect: Indirect)
    Exercise: $2.75Exp: 2011-12-21→ Common Stock (333,333 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 2 total(indirect: Indirect)
    Exercise: $0.38Exp: 2011-12-31→ Common Stock (333,333 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05−1→ 0 total(indirect: Indirect)
    Exercise: $1.60Exp: 2010-12-31→ Common Stock (500,000 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 3 total(indirect: Indirect)
    Exercise: $0.38Exp: 2011-12-31→ Common Stock (500,000 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05−1→ 0 total(indirect: Indirect)
    Exercise: $1.74Exp: 2011-12-31→ Common Stock (372,552 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 4 total(indirect: Indirect)
    Exercise: $0.38Exp: 2011-12-31→ Common Stock (372,552 underlying)
  • Other

    Common Stock Warrant (right to buy)

    2011-01-05+1→ 1 total(indirect: Indirect)
    Exercise: $0.38Exp: 2011-12-31→ Common Stock (256,148 underlying)
Holdings

  • Common Stock

    (indirect: Indirect)
    984,615
Footnotes (11)
  • [F1]1,034,482 of these shares were acquired by Inverlochy Consultadoria e Servicos Lda ("Inverlochy") on December 10, 2008 pursuant to a purchase agreement with the Issuer that provides that the Issuer, rather than the holder, has all voting rights in respect of such shares through December 31, 2011, and that the holder may not transfer such shares through December 31, 2011 except for transfers to Affiliates (as defined therein). On June 29, 2010, Inverlochy merged with and into Taufin International S.A. ("Taufin"), its direct parent, which is a direct wholly-owned subsidiary of Taufin S.p.A. Taufin S.p.A. is owned by Claudio Cavazza.
  • [F10]The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on September 16, 2006.
  • [F11]The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on December 21, 2006.
  • [F2]Securities directly owned by Taufin.
  • [F3]Securities directly owned by Defiante Farmaceutica S.A. ("Defiante"). Defiante is 58% directly owned by Sigma Tau Finanziaria S.p.A. ("Sigma Tau") and 42% directly owned by Sigma Tau's wholly-owned subsidiary, Sigma Tau International S.A. Claudio Cavazza directly and indirectly owns 57% of Sigma Tau.
  • [F4]Securities directly owned by Sigma Tau.
  • [F5]The Warrant was issued by the Issuer to the holder in consideration of the holders's purchase of Common Stock.
  • [F6]The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on September 16, 2006.
  • [F7]The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on December 21, 2006.
  • [F8]The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on February 29, 2008.
  • [F9]The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the issuance of a replacement warrant. The warrant became exercisable on December 10, 2008.

Documents

1 file

Issuer

REGENERX BIOPHARMACEUTICALS INC

CIK 0000707511

→
Entity typeother

Related Parties

1
  • filerCIK 0001164803

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 12:52 PM ET
Size
43.0 KB
View on SEC.gov